Background Eosinophilic inflammation, which may be a consequence of interleukin-5 action,
is a characteristic feature of some forms of asthma. However, in three previous clinical trials …

Background In patients with severe eosinophilic asthma, local maturation rather than systemic
recruitment of mature cells might contribute to persistent airway eosinophilia. Group 2 …

Background Autoimmunity has been reported in patients with severe coronavirus disease
2019 (COVID-19). We investigated whether anti-nuclear/extractable-nuclear antibodies (ANAs/…

Rationale: Clinical benefits of fixed-dose 100-mg subcutaneous (SC) mepolizumab in
prednisone-dependent patients are modest when sputum eosinophilia is not adequately controlled…

Background The persistence of eosinophils in sputum despite high doses of corticosteroids
indicates disease severity in asthmatic patients. Chronic inflamed airways can lose tolerance …

Background In clinical trials, the two anti-interleukin (IL)-5 monoclonal antibodies (mAbs:
mepolizumab and reslizumab) approved to treat severe eosinophilic asthma reduce …

BACKGROUND: Sputum cell counts have identified inflammatory subtypes of bronchitis in
relatively small numbers of subjects with asthma, chronic obstructive pulmonary disease (…

… Angira Dasgupta, Melanie Kjarsgaard, Dante Capaldi, Katherine Radford, Fernando
Aleman, Colm Boylan, Leonard C. Altman, Thomas N. Wight, Grace Parraga, Paul M …

To the Editor, There is paucity of data on immune responses to COVID-19 in severe
asthmatics treated with biologics. Recent guidelines recommend continuing these agents (as …

Rationale: Eosinophilic granulomatosis with polyangiitis (eGPA) is a small-vessel vasculitis
where 40% of patients present with serum antineutrophil cytoplasmic antibodies (ANCAs). …